Article
Phase 1/2 trial of brigatinib plus panitumumab in patients with osimertinib-resistant EGFR-mutated non-small cell lung cancer harboring EGFR C797S mutation.
Cancer treatment and research communications - 1 Jan 2026
Izumi Hiroki, Sakamoto Tomohiro, Uchibori Ken, Nishino Kazumi, Sakakibara-Konishi Jun, Katayama Ryohei, Nomura Shogo, Matsumoto Shingo, Udagawa Hibiki, Shibata Yuji, Sakai Tetsuya, Nosaki Kaname, Zenke Yoshitaka, Yoh Kiyotaka, Niho Seiji, Goto Koichi
Abstract excerpt
BACKGROUND: Osimertinib is a standard treatment for advanced EGFR-mutated non-small cell lung cancer (NSCLC). The EGFR C797S mutation is one of the most common resistant mechanisms to osimertinib. Based on our preclinical data, the safety and efficacy of brigatinib combined with panitumumab was evaluated in phase 1/2 study. METHOD: This open-label phase 1/2 study enrolled patients with osimertinib-resistant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.